Investigation Launched into Geron Corporation: Potential Securities Law Violations
New York, NY – March 7, 2025:
Levi & Korsinsky, a leading securities law firm, announced today that it has initiated an investigation into Geron Corporation (Geron) (NASDAQ: GERN) regarding potential securities laws violations. The investigation comes following the biotechnology company’s financial results announcement for the fourth quarter and full year 2024, which was disclosed on February 26, 2025.
Background
Geron Corporation is a clinical-stage biotechnology company focusing on the discovery and development of therapeutic candidates for the treatment of cancer and age-related diseases. The company’s lead product candidate, Imetelstat, is a potential treatment for myelofibrosis, a bone marrow disorder. The announcement of the financial results included a significant decrease in revenue and an increase in net loss compared to the same period in the previous year.
Investigation Details
Levi & Korsinsky, on behalf of Geron investors, is investigating the company’s financial reporting practices and whether the financial statements for the fourth quarter and full year 2024 were accurate and complete. The firm is examining whether Geron Corporation and certain of its executives or directors violated federal securities laws by making false and/or misleading statements and/or failing to disclose material information.
Impact on Individual Investors
Individual investors who purchased or otherwise acquired Geron Corporation securities between February 1, 2023, and February 26, 2025, may contact Levi & Korsinsky to discuss their options for recovering their investment losses. The investigation may lead to a class action lawsuit against Geron Corporation. If a class action is certified, investors may be entitled to recover damages for their losses.
Global Consequences
The potential consequences of this investigation could extend beyond Geron Corporation. The biotech industry as a whole may face increased scrutiny as investors and regulatory bodies demand transparency and accurate reporting. This could lead to increased regulatory oversight and stricter financial reporting requirements. Additionally, investor confidence in the sector could be impacted, potentially leading to decreased investment in biotech companies.
- Increased regulatory oversight and stricter financial reporting requirements for biotech companies
- Decreased investor confidence in the biotech sector
- Potential negative impact on other biotech companies’ stock prices
Conclusion
The investigation into Geron Corporation by Levi & Korsinsky highlights the importance of accurate financial reporting and transparency in the biotech industry. As the industry continues to evolve and attract significant investment, it is crucial that companies maintain the trust of their investors and regulatory bodies. The potential consequences of this investigation extend beyond Geron Corporation and could impact the biotech sector as a whole. Investors are encouraged to stay informed and seek professional advice if they believe they have been affected by potential securities law violations.
Levi & Korsinsky is committed to ensuring that companies adhere to ethical business practices and provide full disclosure to their investors. If you purchased or otherwise acquired Geron Corporation securities between February 1, 2023, and February 26, 2025, and wish to discuss this investigation or potential recovery options, please contact Levi & Korsinsky, LLP via email at [email protected] or call 212-363-7500. The firm’s team of attorneys will review the merits of your claim and provide guidance on how to recover your losses.
